Clopidogrel-Repaglinide-DDI

Modeling of published clinical Clopidogrel-Repaglinide-DDI studies for model evaluation

Repository files

Within this repository, we distribute a PK-Sim project file containing simulations of all published clinical studies used to evaluate the predictive performance of the clopidogrel model regarding the clopidogrel-repaglinide-DDI, including the respective observed data digitized from literature reports. The applied repaglinide model has been published previously [1]. For further details and documentation please refer to [2].

Version information

PK-Sim Version 9.1.

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model is distributed under the GPLv2 Lincense.

Reference

[1] Türk, D.; Hanke, N.; Wolf, S.; Frechen, S.; Eissing, T.; Wendl, T.; Schwab, M.; Lehr, T. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug–drug–gene interactions: A modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin. Pharmacokinet. 2019, 58, 1595–1607.

[2] Loer, H.L.H.; Türk, D.; Gómez-Mantilla, J.D.; Selzer, D.; Lehr, T. Physiologically based pharmacokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 drug-drug-gene interaction predictions. Pharmaceutics 2022, 14, 915.